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Abstract
Background: In recent years, the incidence rate of thyroid cancer is increasing rapidly,
including a significant increase in young aged group people. Environmental chemical exposure is
a significant driver. With untargeted metabolomics approach, this study will perform an
untargeted metabolomics approach to identify serum metabolites biomarkers associated with
thyroid cancer and tumor size.
Methods: Serum samples of 100 thyroid cancer patients (50 cases and 50 controls) diagnosed
between 2010 and 2011, were extracted for metabolites and analyzed by reversed-phase liquid
chromatography-mass spectrometry (LC-MS) based untargeted metabolomics. All the analysis
were conducted in both positive and negative Electrospray ionization (ESI) modes. Multivariate
and univariate data analysis tools are applied to identify metabolic differences among different
sample groups and metabolites associated with the thyroid cancer cases.
Results: No significant metabolic difference through multivariate analysis were observed
among different sample groups (small case, large cases and controls). One metabolite
methylcytosine [M-H2O-H] was identified through univariate analysis in the ESI negative mode
when comparing cases (small cases and large cases) and controls, which can be caused by
environmental exposure.
Conclusions: There were no significant metabolic differences among different sample groups.
One metabolite methylcytosine [M-H2O-H] of thyroid cancer was identified. Future research
with a larger sample size and measurement of environmental chemicals in cancer patients are
needed to uncover the association between environmental chemical exposure and thyroid cancer.

Keywords: Thyroid cancer, Environmental Chemicals, Endocrine disrupting, Untargeted
metabolomics, Biomarkers
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1. Introduction
In recent years, the incidence rate of thyroid cancer (mainly for papillary thyroid
carcinoma) is increasing rapidly, and it is also the fastest increasing cancer among all the
cancers in the US [1]. According to the US Surveillance, Epidemiology and End Results,
the incidence increase rate of thyroid cancer is 3.6% per year on average from 1974 to
2013, and it has increased more than three times from 4.56 per 100,000 person-years
(1974-1977) to 14.42 per 100,000 person-years (2010-2013) [2]. Thyroid cancer is also
estimated to be the fourth cancer type for diagnosis in the US by 2030, and the societal
cost is estimated to exceed $3.5 million by 2030 [3,4]. Moreover, there is a significant
increase of thyroid cancer incidence among young aged people, who don’t usually have
imaging exams [3, 5]. It is very important to find out the underlying causes about the
rapid increase of thyroid cancer incidence for thyroid cancer prevention strategies.

Although improved diagnostic imaging methods are partly responsible for the increase of
the thyroid cancer, it can only explain around 50% of the increase in recent decades [6].
The etiology and risk factors for thyroid cancer haven’t been well-understood yet and still
remains largely unknown. Currently, one well-established risk factor driving the increase
of thyroid cancer is ionizing radiation especially during childhood [7]. There are also
many other possible factors, such as family history of thyroid cancer, dietary habits,
lifestyle change, excess bodyweight and height, sex, iodine intake and other risk factors
[4,7,8]. In particular, many studies have indicated that environmental chemical exposure
is a significant potential driver for the increase of thyroid cancer, given their wide
presence and high dispersion in the environment [3, 9, 10, 11, 12].

Most of the chemicals in the environment and consumer products are endocrine
disrupting chemicals (EDCs), including organophosphate flame retardants (PFRs),
polybrominated diphenyl ethers (PBDE), polybrominated biphenyls (PBB),
polychlorinated biphenyls (PCBs), perfluorinated compounds (PFCs), bisphenol A
(BPA), phthalates, organophosphate pesticides and so on [13]. In human studies, several
of these EDCs have shown their thyroid disrupting properties, and the disruptive
activities include disturbance of thyroid hormones synthesis, interaction with the thyroid
hormone receptor and secretion and metabolism [8]. In addition, thyroid is very sensitive
and susceptible to EDCs, and tend to develop thyroid cancer [14]. However, there is still
a lack of data and information about the carcinogenic effects of EDCs, and there is also
an urgent need to understand the potential mechanisms of EDCs impacting human health.

The novel hypothesis is that the increasing incidence of thyroid cancer is due to the
influence of environmental exposure causing procarcinogenic biology in the individuals.
However, in this study, I will only use an untargeted metabolomics approach (which can
identify environmental and endogenous metabolites) to identify metabolites associated
with thyroid cancer and tumor size, in order to identify any differences in metabolism
among different sample groups (small case group, large case group and control group)
and also identify non-invasive serum biomarkers of thyroid cancer. Moreover, as for the
next step, the environmental chemicals in thyroid cancer patients will be measured, and
the environmental chemical exposure will be linked with some of the metabolites
identified in this study. Finally, the correlations between exposure metabolites and
engogenous metabolites will be conducted to assess if the environmental metabolites alter

the biology of the patients. The data analysis results will be interpreted for
prevention/diagnosis strategies of thyroid cancer as the exposome approach can help
identify the early signs and mechanisms of thyroid cancer.

The aim of this study is to identify the serum metabolite biomarkers of thyroid cancer
with untargeted metabolomics data, which can help uncover the association between
environmental chemical exposure and thyroid cancer risks [15].

2. Review of Relevant Studies
Currently, there are many studies on the association between environmental chemical
exposure (especially exposure to ECDs) and the risk of thyroid cancer. Most of the
current studies are animal studies and epidemiological studies, including case-control
studies, cohort studies, and cross-sectional studies. The most commonly studied
chemicals include polychlorinated biphenyls (PCBs), polybrominated diphenyl ethers
(PBDEs), perchlorate, bisphenol-A, phthalates, pesticides, perfluoroalkyl substances
(PFASs) and heavy metals (like cadmium, chromium, lead, mercury). Their mechanisms
of thyroid disrupting activities include alteration of blood stream transport, alteration of
liver metabolism, alteration of biosynthesis, and all steps of thyroid hormone physiology
[16]. The common methods for assessing environmental chemical exposure in these
studies include chemical concentrations in serum/urine samples, metabolites and
questionnaires [4, 16, 17]. However, to my best knowledge, there are no study using
metabolomics approach to uncover the association between environmental chemicals and
thyroid cancer. In terms of the results, there are positive associations between thyroid
cancer risks and environmental chemicals, like heavy metals (Cu, Pb and Cd), certain

flame retardants, phthalates, bisphenols, and certain pesticides [13, 16]. However, as for
other chemicals like PCBs and pesticides, the findings are not consistent and
controversial [16].

However, there are several limitations of animal studies and epidemiological studies for
finding the link between environmental chemical exposure and thyroid cancer risk. These
studies only covered a small proportion of environmental chemicals, and they are often
only targeted on one single chemical exposure every time [18]. Also, they didn’t assess
the long-term health impacts caused by the environmental chemicals (with exposure
changes overtime and the development process of thyroid cancer in human body) [13,
16]. However, the population has usually been exposed to a mixture of different
chemicals in the environment and over a long time period, which might not be well
reflected by current approaches (animal studies and epidemiological studies). There is
still a lack of long-term study of most of the chemicals, as most of them only have been
studied sporadically [16].

Therefore, the approach of nontargeted metabolomics is very important to be applied to
identify serum metabolite biomarkers in thyroid cancer patients, which can help uncover
the link between environmental chemicals and thyroid cancer as it includes the
biocontamination information over a long time.

3. Research Design
Serum samples were collected from 100 individuals (50 cases and 50 controls) in the
Connecticut thyroid cancer population-based case-control study. Eligible cases were
histologically confirmed (papillary, follicular, medullary, and anaplastic) incident thyroid
cancer cases, which are diagnosed between 2010 and 2011 and identified through the Yale
Cancer Center's Rapid Case Ascertainment Shared Resource, part of the CT Tumor
Registry. Among all the 50 cases, there are 24 small cases (tumors < 1cm), including 2
men and 22 women; and 26 large cases, including 8 men and 18 women. Among all the 50
controls, there are 10 men and 40 women. With a metabolome wide association study, the
way how environmental exposures correlate with metabolites will be determined, therefore
identifying new causal pathways linking exposures to thyroid cancer.

Metabolomics data that will be analyzed in this article was previously acquired by the Dr.
Johnson’s Lab in 2019. Briefly, the serum samples (50uL each) were extracted for
metabolites and analyzed by reversed-phase liquid chromatography-mass spectrometry
(LC-MS) based untargeted metabolomics. Quality control (QC) examples are prepared
and analyzed with the same procedure. The QC samples contains a small amount of each
of the samples that were analyzed, and they were analyzed multiple times repeatedly in
the LC-MS analysis to make sure the system is working well and the metabolic data is of
high quality. All the analysis above were conducted in both positive and negative
Electrospray ionization (ESI) modes. Data was processed using xmcs (22) and
CAMERA (49) packages in R. Data was normalized using support vector
regression (50) and available in .csv format for statistical analysis.

Statistical Analysis
Multivariate and univariate data analysis tools are applied to identify
metabolites associated with the thyroid cancer cases.

Principal component analysis (PCA) is used to reveal the differences of metabolic
profiles of serum samples among small cases, large cases and controls. The reliability of
the model is determined by R2 value (explanatory rate) and Q2 value (forecast rate). R2
value represents the percentage of explained variance within the model, and Q 2 value
represents the percentage of predicted variation within the model. And the model is more
reliable with higher R2 and Q2 values (0.6-1.0, and the difference between R2 and Q2 is
no more than 0.2).

Wilcoxon analysis is conducted to identify the significant metabolites, with adjusted p
value < 0.05 at the significance level. Volcano plots were conducted to show the
visualization, and the fold-change and p values were log transformed.

All analysis is performed with R studio (Version 1.4.1106). Metabolites are identified
with an in-house database and comparison of mass spectral information to additional
databases such as METLIN (36).

4. Results
4.1 Serum untargeted metabolomics analysis in positive ESI mode

4.1.1 Multivariate data analysis

In the positive ESI mode, Figure 1 shows that the QC samples in the PCA model are well
clustered, which indicate good reproducibility in the LC-MS analysis. Even though the
QC samples should be in an identical position within the plot in theory, there hasn’t been
any instrumental drift, and it can still indicate the stability of the mass spectrometry run
and the good quality of the data.

The model statistic R2 values are 0.085 and 0.043 for PC1 and PC2, respectively. And Q2
values are 0.063 and 0.084 for PC1 and PC2 respectively. R2 and Q2 values are quite low,
which indicates that the model doesn’t show metabolic variation between different
sample groups.

Figure 1 PCA scores plot with quality control (ESI positive mode)

In Figure 2, the blue circle, orange triangle and gray cross represent the large case group,
the small case group and the control group, respectively. There is a relative dispersion of
three groups of samples, and the samples are clustered within their groupings, indicating
differences in serum metabolome in different groups. Each blue circle represents one of

the large tumors analyzed, and all the blue circles are quite clustered tightly, so their
metabolomic profiles are more similar than the controls or smaller tumor case group. The
smaller cases (orange triangles) are a little more dispersed within their grouping, but still
residing in the same space. However, the controls (gray cross) are relatively more
dispersed on the plot but still grouped together, indicating that the metabolic profiles are
more varied among health controls.

The explained variances on PC1 and PC2 are quite low. The models don’t explain much
variation between the controls and cases, as the total data variance explained by PCA
model is only 12% (PC1 = 8% explained variance, PC2 = 4 % explained variance). The
model statistic R2 values are 0.085 and 0.043 for PC1 and PC2, respectively. Q2 values
are 0.061 and 0.0068 for PC1 and PC2 respectively.

It’s interesting to observe that there is visual separation in metabolomes between
controls, and cases by tumor size; but the percentage of variance explained by the model
is low. This may be due to the small sample size (n = 100) in this study, and further
researches are needed to investigate more about the metabolic variation among different
sample groups (small case, large case and control) with a larger sample size.

Figure 2 PCA scores plot (ESI positive mode)

4.1.2 Univariate data analysis
Wilcoxon analysis is applied to identify the significant metabolites, and volcano plot is
used to visualize the statistical results and identify the significant metabolites between the
case group (small and large cases) and control group. Figure 3 shows that there is no
significant metabolite between the case group and control group after multiple
comparisons. Moreover, as the control group and large case group are more separated in
the plot, they were also compared (Figure 4). However, there is still no significant
metabolite observed.

Figure 3 Volcano plot of metabolic differences between cases and controls (ESI positive mode)

Figure 4 Volcano plot of metabolic differences between large cases and controls (ESI positive mode)

4.2 Serum Metabolomics profile analysis in negative ESI mode

4.2.1 Multivariate data analysis
In the negative ion mode, Figure 5 shows that the QC samples in the PCA model are well
clustered, which indicate good reproducibility in the LC-MS analysis and good data
quality, although the QC samples are not in an identical position within the plot.

The model statistic R2 values are 0.075 and 0.065 for PC1 and PC2, respectively. Q2
values are 0.026 and 0.069 for PC1 and PC2 respectively.

Figure 5 PCA scores plot with quality control (ESI negative mode)

In Figure 6, the blue circle, orange triangle and gray represent the case group with large
tumors, the case group with small tumors and the control group, respectively. In terms of
visual inspection, there is not an obvious dispersion of three groups of samples,
indicating that there are not obvious differences in serum metabolome in different groups.
There is also almost no separation between small cases and large cases, indicating that
there is no metabolic variation between small cases and large cases. However, the
separation between the case group (small cases and large cases) and control group is
observed, indicating that there might be metabolic variation between case group and
control group.

The explained variances on PC1 and PC2 are also quite low in the negative ESI mode.
The models don’t explain much variation between the controls and cases, as the total data

variance explained by PCA model is 15% (PC1 = 8% explained variance, PC2 = 7 %
explained variance). The model statistic R2 values are 0.076 and 0.066 for PC1 and PC2,
respectively. Q2 values are 0.030 and 0.074 for PC1 and PC2 respectively.

Figure 6 PCA scores plot (ESI negative mode)

4.2.2 Univariate data analysis
The volcano plot (Figure 7) shows that there are two significant metabolites between the
case group (small cases and large cases) and control group after multiple comparisons. In
our analysis, the univariate analysis generated a table with FDR-corrected p-values, the
identifiers in the table are m/z = 106.0417, wilcox.p value= 5.29E-14, wilcox. adjusted p
values (fdr) = 6.57E-10, fold change difference between cases and controls = 0.299684;
and m/z = 408.283, wilcox.p value = 1.16E-13, wilcox. adjusted p values (fdr) = 7.21E-10,
fold change difference between cases and controls = 2.706164.

The putative identification for metabolite 106.0417 is methylcytosine [M-H2O-H]. The
mass error 6.19 ppm, and it’s upregulated 2.7-fold in the thyroid cancer cases. Moreover,

this metabolite is a biomarker for DNA damage, which can be caused by environmental
exposures.

There are a few putative identifications for metabolite 408.283. However, the
identifications might only be putative, because the mass error is larger (> 13 ppm). For
example, some identifications to METLIN with a mass error below 20 ppm include 3,5Didecanoylpyridine (mass error 13.39 ppm); 3-Hydroxy-10'-apo-b,y-carotenal (mass error
19.27 ppm); and 20, 22-Dihydrodigoxigenin (mass error 18.1ppm). However, the
identification of metabolite 408.283 needs further investigation.

Figure 7 Volcano plot of metabolic differences between cases and controls (ESI negative mode)

5. Discussion
In this study, the serum samples were analyzed in both positive and negative ESI modes to
examine different metabolites within the widest range of metabolites possible. And two

significant metabolites were found in the negative mode when all cases (small cases and
large cases) and controls were compared.

In the positive ESI mode, there is a dispersion of different sample groups (small case, large
case and control) by visual examination of the PCA model, indicating trends of metabolic
differences among different groups. However, the total variance explained by PCA (12%)
is low. Moreover, none of the metabolites were statistically significant. The reason might
be that this study is under power with the small sample size (n =100), and future research
are needed to further examine the metabolic differences among different sample groups
(small cases, large cases and control) with a larger sample size, and also identify significant
metabolites.

In the negative ESI mode, there is a dispersion of the cases (small tumor and large tumor)
and controls by visual examinations of the PCA model; however, there is almost no
dispersion between small case group and large case group. This indicates that there might
be metabolic differences between the cases and controls. However, the total variance
explained by PCA (15%) is also relatively low. Similar to the positive mode, the reason
might be that this study is under power with a small sample size (n =100). Further
researches are needed to examine the metabolic differences between controls and all the
cases (small tumor and large tumor) with a larger sample size.

And in the negative mode, two metabolites were identified to have the association with
thyroid cancer (metabolite 106.0417 and metabolite 408.283) when cases (small tumor and

large tumor) and controls were compared. The putative identification for metabolite
106.0417 is methylcytosine [M-H2O-H], which is a biomarker for DNA damage and can
be caused by environmental exposures. Further, we still need to confirm the identification
in Dr.Johnson’s Lab. However, the identification of metabolite 408.283 may only be
putative (mass error >13 ppm) and still needs further investigation.

Moreover, methylcytosine [M-H2O-H] has also been proved to be a marker to monitor
DNA methylation [19]. And DNA methylation has been proved as epigenetic changes for
many existing environmental chemicals, including arsenic, nickel, chromium, mercury,
lead, BPA and pesticides [20]. Also, methylcytosine [M-H2O-H] has also been previously
reported as a biomarker of DNA damage, and it can be caused by environmental chemical
exposure.

There are several studies on the metabolomics of thyroid cancer appearing in the past few
years, and the three most referred metabolites are choline, lactate and tyrosine, and other
identified metabolites include leucine, lysine, phenylalanie, citrate, and so on [21]. These
metabolites are different from the two metabolites identified in my study, and this might be
due to different methods, study groups, study site, samples (like serum and tissue) and
different sample size used in different studies, and future research can be conducted with
more similar populations and samples and a larger sample size (higher possibility to
identify more significant metabolites).

The Importance of this study
It’s also very interesting to notice the rapid increase of thyroid cancer cases in the past few
years especially among the young aged group, as there is not much change happening
among the population in the past few decades. It is hard to find out the causes, but it is very
important to find out the underlying biology and develop thyroid cancer prevention and
diagnosis strategies. Environmental chemical is a potential big risk factor due to its thyroid
disrupting activities and huge surge in production and application (household products,
agriculture, buildings, food packaging, drinking water, medical product, and so on) in the
last few decades [22]. The existence of artificial chemicals is ubiquitous in the
environment, and the exposure pathways can be through skin contact, diet, inhalation of
household dust, air pollution [13, 16]. The novel hypothesis is that the increasing incidence
of thyroid cancer is due to the influence of environmental exposure causing
procarcinogenic biology in the individuals. In this study as the first step, the serum
metabolites associated with thyroid cancer and tumor size were identified, in order to
identify any differences in metabolism among different sample groups (small case group,
large case group and control group) and also identify non-invasive serum biomarkers of
thyroid cancer.

Moreover, the individuals are usually exposed to different kinds of environmental
chemicals at the same time, and there is also a biological development process of thyroid
cancer over time. However, most of the existing studies (such as animal studies and
epidemiological studies) mainly focus on one specific environmental chemical. Untargeted
metabolomics is an innovative approach to measure the environmental chemical exposure

accurately, understand the disease aetiology with individual exposotype, and help uncover
the association between environmental chemicals and thyroid cancer, for the benefit of
thyroid cancer prevention and diagnostic strategies in the public health practice [20].

6. Conclusions
6.1 Summary of findings
There are potential metabolic differences between the case group (including small cases
and large cases) and the control group of thyroid cancer by visual examination of PCA
model. Moreover, there are also potential metabolic differences between the small case
group and large case group of thyroid cancer by visual examination of PCA model.
However, in both positive and negative modes, the total variances explained by PCA are
relatively low. This might be explained by the low power of the study (sample size = 100),
and future researches are needed to investigate the metabolic differences between cases and
controls and also cases by tumor size using a larger sample size.

The study has identified two significant metabolites. The certain one is metabolite
methylcytosine [M-H2O-H]. It is related to DNA damage, and it can be caused by
environmental chemical exposure. Furthermore, it’s also important and potential to identify
more significant metabolites with a larger sample size in future research.

Considering the long-term exposure to mixed environmental chemicals of the population,
untargeted metabolomics is an important and innovative approach to measure the
environmental chemical exposure accurately, understand the disease aetiology with

individual exposotype, which can help uncover the association between environmental
chemicals and thyroid cancer, for the benefit of thyroid cancer prevention and diagnostic
strategies in the public health practice

6.2 Limitations
Although there is dispersion of different sample groups observed by visual inspection in the
PCA model, the R2 values and Q2 values are very low in both positive and negative ESI
modes. This might be explained by the power of the study with a sample size of 100. To
further investigate the metabolic difference, a larger sample size of serum samples of
thyroid is needed for future research.

The numbers of men and women in each sample group are not equal. In the small case
group, the ratio of men to women is 1:11; in the large case group, the ratio of men to
women is 4:9; and in the control group, the ratio of men to women is 1:4. Although there is
a higher thyroid cancer incidence in women than men and all the samples are at the same
age, the separation of different sample groups in the PCA model might be driven by gender
difference instead of metabolic information difference. Future research is needed to make
sure the numbers of men and women are equal in each sample group.

6.3 Recommendations for further research
I’ve found potential metabolic differences between different sample groups by visual
inspection in the PCA model (even though total data variance explained by PCA is low),
and also identified two significant metabolites. However, the sample size (n=100) in the
study might have limited the significant metabolites of thyroid cancer. It’s very important
to increase sample size in the future and hopefully identify more significant metabolites.

The biomarker methylcytosine [M-H2O-H] found in the study indicates that the pathway
that environmental chemicals might cause thyroid cancer is through DNA damage. As it is
putative identification, we still need to confirm it in Dr. Johnson’s lab. It’s important for
future research to further prove the link of DNA damage between different environmental
chemicals and thyroid cancer.

In this study, I only conducted the first step of identifying serum metabolites of thyroid
cancer patients. Future researched are needed to measure environmental chemicals in
patients who have thyroid cancer. The rationale is that the chemicals might effect tumor
progression or prognosis (they could effect cellular processes such as immune responses, or
they could have other signaling/metabolic effects that could propagate tumor growth).

The environmental chemical exposure will be linked with some of the metabolites
identified in this study. Moreover, the correlations between exposure metabolites and
engogenous metabolites will be conducted to assess if the environmental metabolites alter
the biology of the patients.
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